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a b s t r a c t
A large part of the scientiﬁc community has accepted the paradigm that a simulated body solution (SBF)
can be used to test the bioactivity of a material. This is exempliﬁed by the rapidly increasing number of
publications using this test. The aim of this document is to demonstrate that (i) there is presently not
enough scientiﬁc data to support this assumption, and (ii) even though the assumption was valid, the
way the test is generally conducted leaves room for improvement. Theoretical arguments and facts
supporting these statements are provided, together with possible improvements of the proposed
bioactivity test.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
1.1. A short history of SBF
Two decades ago, Kokubo et al. [1,2] used SBF to perform in vitro
simulations of in vivo conditions. In 2003 a revised SBF solutionwas
proposed to take into account the fact that a large proportion of
calcium and magnesium species present in serum is bound to
proteins and hence unavailable for apatite precipitation [3]. The
revised SBF solution had a 40% lower calcium concentration and
a 33% lower magnesium concentration.
Since 1987, the use of SBF for bioactivity testing has exploded. A
search in Scopus (www.scopus.com) using the keywords ‘‘bioac-
tivity’’ and ‘‘simulated body ﬂuid’’ (in all ﬁelds) leads to 1975 hits
(Jan 5, 2009) with 379 hits in 2008. In 2006, Kokubo and Takadama
reviewed the topic in a paper entitled ‘‘How useful is SBF in pre-
dicting in vivo bone bioactivity?’’ [1] and reiterated the statement
that SBF could be used to test bioactivity. After 20 years of research
in this ﬁeld, the opinion shared by a large part of the biomaterials
community is that the formation of apatite on a material dipped in
SBF is a proof of its bioactivity and can be used to anticipate its bone
bonding ability in vivo.
1.2. Bioactivity
According to the ESB consensus conference of 1987 [4],
a bioactive material is ‘‘one which has been designed to induce
speciﬁc biological activity’’. Obviously, there has been a drift of
meaning over time, because Kokubo and Takadama [1] consider
bioactive materials as bone bonding materials. More speciﬁcally,
these authors state that ‘‘.the essential requirement for a material
to bond to living bone is the formation of bone-like apatite on its
surface when implanted in the living body’’, and that ‘‘.this in vivo
apatite formation can be reproduced in a simulated body ﬂuid (SBF)
with ion concentrations nearly equal to those of human blood
plasma.’’ Thus, according to Kokubo and Takadama’s deﬁnition of
bioactivity, a bioactive material is a material on which bone-like
hydroxyapatite will form selectively after it is immersed in
a serum-like solution [1,5]. Despite the absence of recommendation
of Kokubo regarding the CO2 partial pressure (p(CO2)), it is worth
mentioning that the use of physiological conditions implies that the
test should be performed at p(CO2)¼ 0.05 atm (5%) since human
serum is in equilibrium with such a partial pressure.
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2. Crystallization theory
Crystallization theory suggests that bone bonding ability (or
bioactivity) and apatite formation in SBF solution are two distinct
phenomena. To explain this statement, it is necessary to review
basic principles of crystallization theory and relate these principles
to the SBF-based bioactivity test.
Thermochemical calculations show that serum and SBF are
supersaturated towards apatite crystals [6]. In other words, the
system is metastable and will eventually become thermodynami-
cally stable by forming apatite crystals. It is just a matter of time
[7,8]. This time, called induction or nucleation time, depends not
only on the ease but also on the rate at forming crystal nuclei large
enough to be thermodynamically stable and hence large enough to
grow (the size above which crystals are stable is generally referred
as critical size). So, when apatite crystals form or precipitate on
a piece of material dipped in serum or SBF, it simply means that the
dipping time was longer than the induction time. Understanding
the factors affecting nucleation is therefore essential to understand
the outcome of bioactivity experiments performed with SBF.
2.1. Critical size nucleus
In order for a stable crystal to form, it has to overcome the
activation energy for crystallization. This energy is the result of the
balance between the energy increase due to the formation of a new
solid-solution interface and the energy decrease due to the crystal
formation. Thus, as the surface to volume ratio is proportional to 1/r
where r is the particle radius, a minimal (critical) particle radius, rc,
must be reached [8]:
rc ¼ 2basV=ð3bvRT ln SÞ
In this equation, ba and bv are geometric factors related to the area
and the volume of the precipitating nuclei, s is the free energy per
unit area of the nucleus-solution interface, V is the molar volume of
the precipitate, T is the temperature and R is the gas constant; S is
the saturation ratio, i.e. the ratio of the actual concentration of
dissolved precipitate to its concentration at thermodynamic equi-
librium. This equation is valid for nuclei forming in a solution, and is
referred to as homogeneous nucleation.When nuclei are formed on
a solid surface, one refers to heterogeneous nucleation. In that case,
the surface free energy between nucleus and solid must also be
considered. Since it is generally lower than s, the critical size is
lower and nucleation is easier. In that context, it is interesting to
note that Kokubo and Takadama [1] advice to perform bioactivity
tests in ‘‘a plastic container with smooth surface and without
scratches (.) because apatite nucleation can be induced at the
surface of a glass container or the edge of scratches’’.
2.2. Production rate of critical size nuclei
Beside the ease at nucleating a critical size nucleus, a second
aspect of importance for crystallization is the rate at which crystal
size nuclei are generated. This rate can be written as [8]
JðtÞ ¼ Joexpðt=sÞ
where Jo is the steady state nucleaction rate, t is the time and s is the
induction time or time constant which is itself expressed as
t ¼ 6d2n*=ðD ln SÞ
where d is the molecular diameter, n* is the critical number of
atoms, molecules or ions in the critical size nucleus, D is the
diffusion coefﬁcient; S is the saturation ratio already deﬁned above.
3. Apatite formation in SBF and crystallization theories
Relating these theories to dipping tests in SBF, it becomes clear
that a ‘‘bioactive’’ compound according to Kokubo’s deﬁnition [1,5]
is a material that accelerates heterogeneous apatite crystallization
in a solution supersaturated towards hydroxyapatite. This can be
achieved by several strategies: (i) providing apatite nuclei that
remove the need to nucleate apatite crystals, (ii) providing a surface
with a low interfacial energy with apatite, or (iii) changing the local
supersaturation towards apatite precipitation. The ﬁrst strategy
explains why hydroxyapatite is rapidly covered with new apatite
crystals [9,10]. The second strategy gives an explanation for the
formation of apatite on b-TCP surface [10] (importantly, b-TCP
behaves as an ‘‘inert’’ material in SBF since b-TCP is insoluble in SBF
[11,12]). It can also be related to the advice of Kokubo and Takadama
[1] to use ‘‘plastic containers with smooth surface and without any
scratches (.) because apatite nucleation can be induced at the
surface of a glass container or the edge of scratches’’. The third
strategy explains why bioglass and other materials such as calcium
sulphate hemihydrate (CSH) are rapidly covered by an apatite layer
upon immersion in SBF. Since several sub-strategies exist, the third
strategy is discussed in more details hereafter.
3.1. Change of local supersaturation
The addition of a solid into SBF can modify the solution
composition and hence the supersaturation provided is at least
partly soluble in SBF. A local change of supersaturation can either be
positive thus favouring apatite formation or negative hence pre-
venting apatite formation. Taking the case of bioglass, this material
is basic and hence provokes a local pH increase of SBF [13–19]. This
increase can easily reach two pH units which leads to a 10–100-fold
decrease of HA solubility [6], and accordingly, a very large accele-
ration of apatite nucleation. This effect is reinforced by the release
of calcium ions from bioglass [14,16].
Another way tomodify locally the solution composition is to use
a material soluble in SBF that can release large quantities of calcium
and/or phosphate ions. This is the case of CSH (solubility close to
100 mM Ca ions – serum: 1.6 mM) [20], calcium sulphate dihydrate
(CSD; solubility close to 10 mM Ca ions) [20] and dicalcium phos-
phate dihydrate (DCPD) [6] despite the fact that in vivo results have
shown that CSH, CSD, and DCPD are resorbed too fast to form
a direct bond with bone [21–23].
Beside a pH change or a release of calcium and phosphate ions,
a material can also change the local saturation by releasing ions
incorporated in poorly soluble apatites. For example, the release of
ﬂuoride ions from a material could increase the local saturation of
SBF towards ﬂuoroapatite. However, to our knowledge, there are no
studies related to such a mechanism.
3.2. Volume, size and kinetics effects
In a previous paragraph, it was described how a change of local
SBF composition provoked a change of supersaturation resulting in
a deceleration or acceleration of apatite precipitation. Obviously,
local dynamics can have an impact on the reaction kinetics. For
example, Vallet-Regi et al. [14,17] have shown that the use of
a dynamic rather than a static incubation solution postponed
apatite formation. Similarly, an increase of the material surface area
(e.g. using granules instead of dense forms) leads to faster changes
of the local SBF composition and hence to an earlier apatite
formation [18,19]. Also, a change of the material/liquid ratio is
expected to modify the rate of apatite formation. In fact, changes in
the experimental settings could provoke a change in the outcome
of the test.
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4. Bioactivity testing using SBF
In their ‘‘leading opinion paper’’, Kokubo and Takadama [1]
concluded that ‘‘a material able to have apatite form on its surface
in SBF has apatite produced on its surface in the living body, and
bonds to living bone through this apatite layer’’. This conclusion is
contradicted by the observation done with CSH and DCPD, which
both showan apatite layer forming in SBF [10,24] but no direct bone
bonding in vivo [21–23,25]. These authors also concluded that
‘‘examination of apatite formation on the surface of a material in
SBF is useful for predicting the in vivo bone bioactivity of the
material, not only qualitatively, but also quantitatively’’. This
statement is contradicted by the fact that b-TCP does not always
lead to apatite formation in SBF despite its extensive bonding to
bone [26,27]. It would also be contradicted by dipping a non-
biocompatible apatite forming substance such as cadmium- or
lead-containing apatite.
The collection of results presented here indicates that among
the few most signiﬁcant mineral bone substitutes used in vivo
(bioglass, b-TCP, CSH, HA, DCPD), bioactivity testing with SBF may
lead not only to false positive but also to false negative results.
Therefore, it appears correct to state that ‘‘in vitro bioactivity tests
in SBF solutions cannot be used to predict the in vivo bone bonding
ability of a material’’.
4.1. Variability of SBF solutions
Since the ﬁrst disclosure of the composition of SBF [2,5], several
new SBF compositions have been proposed [3,28,29]. However,
none of these solutions correspond to the composition of human
blood serum. The threemain differences between SBF solutions and
serum are (i) the absence of proteins, whereas they are known to
play an essential role in controlling apatite nucleation (nucleation
inhibitors) [10,30]; (ii) the addition of TRIS to buffer SBF solutions,
and (iii) the absence of control of the carbonate content of SBF
solutions, although carbonates act as pH buffer in serum [31]. Thus,
current SBF compositions look somewhat arbitrary and often far
from the blood serum they are supposed to simulate. The only
requirement apparently retained for a SBF to test the ‘‘bioactivity’’
of a material is that it can precipitate hydroxyapatite at the physi-
ological temperature (37 C).
The supersaturation of SBF solutions with respect to various
calcium phosphates has been calculated recently by Lu and Teng
[6]. These authors demonstrated that all SBF solutions proposed so
far are supersaturated towards HA and OCP precipitation and
undersaturated towards DCPD precipitation. Unfortunately, these
authors did not consider the carbonate content of the SBF solution
despite the fact that blood serum is in equilibrium with a partial
pressure of carbon dioxide (CO2) close to 0.05 atm [31], which is
a key factor in pH buffering of blood.
Therefore, any solution that would meet the following criteria
could be proposed as an alternative SBF solution: (i) Simpliﬁed
composition, incorporating only the main inorganic ions present in
blood serum (Naþ, Ca2þ, Cl, HCO3, HPO4). (ii) Biomimetic
composition, mimicking the main features of blood serum (ionic
strength around 140 mM, initial Ca concentration around 2.5 mM
and pH¼ 7.4). (iii) Thermochemical status: the solution is in equi-
librium with DCPD in physiological conditions (T¼ 37 C, partial
CO2 pressure¼ 0.05 atm and pH¼ 7.4).
A selection of SBF compositions are compared in Appendix I.
4.2. Procedure to produce SBF
The method proposed by Kokubo and Takadama [1] to prepare
SBF solution is tricky, which increases the risk of obtaining non
reproducible results: (i) The SBF preparation procedure performed
at 37 C under stirring increases the risk of premature calcium
phosphate precipitation. (ii) The solutions are not ﬁltered at any
point, although the presence of insoluble contaminants can have
a signiﬁcant effect on precipitation [7]. (iii) The carbonate content
of the solutions is not controlled, although it can affect the solution
pH (through exchange with the atmosphere) and change the
saturation levels of calcium phosphates and carbonates [32].
Ideally, the preparation of SBF solutions should be easy and
reproducible. In order to meet this objective, the starting materials
could be distributed into two thermodynamically stable stock
solutions that could be prepared and stored for reasonable times
prior to be used in bioactivity tests. The stock solutions should be
prepared in 5% CO2 atmosphere, should be ultraﬁltrated and stored
in tight bottles in the dark until use. They could be equilibrated at
the testing temperature and carefully mixed just before use. An
alternative simpliﬁed preparation of SBF solutions is proposed in
Appendix II.
5. Conclusion
In this paper, it has been shown that the choice of SBF solution
for testing the bone bonding ability of materials is arbitrary.
Moreover, the protocol proposed by Kokubo and Takadama [1] for
preparing SBF solutions leaves room for improvement, since (i) the
procedure is long and tricky, (ii) the solutions are not ﬁltered, and
(iii) the carbonate content is not controlled. Furthermore, the use of
SBF for bioactivity testing leads to false positive and false negative
results. Despite these criticisms, the use of an in vitro protocol for
testing the bone bonding potential of a material remains a very
attractive concept and should be contemplated very carefully. This
opinion is shared by numerous scientists as evidenced by the large
number of papers describing the use of one or another SBF.
However, in our opinion, the basic principles of the method and its
actual use in predicting bone bonding ability need further
elaboration.
If we assume that bioactivity can be indeed tested in vitro, the
following iterative approach to the problem is suggested: (i) Choose
the simplest SBF mimicking the main features of blood serum:
pH¼ 7.4 at 37 C, under p(CO2)¼ 0.05 atm, in equilibrium with
DCPD. (ii) Dip reference materials (CSD, b-TCP, HA, Ti, bioglass
etc.) in the selected solution and correlate their in vitro behaviour
with their in vivo behaviour. The surface state of the tested mate-
rials should be well characterized, and identical in both in vivo and
in vitro tests. (iii) In case no signiﬁcant correlation is found between
the bioactivity tests and the in vivo results, investigate possible
effects of additives (e.g. Mg, K, sulfates, proteins, etc.), until
consistent results are obtained.
Appendix I. Comparison of selected SBF compositions
Four possible SBF solutions have been compared from the
thermodynamic viewpoint, i.e. their saturation level with respect
to selected Ca phosphates and calcite, and their potential for
hydroxyapatite precipitation in physiological conditions. The
calculations have been performed using the computation algorithm
of Vereecke et al. [32].
Table I summarizes the rationale and the main features of the
SBF selection.
Table II presents the compositions of the selected SBF in terms of
inorganic ion concentrations: c-SBF2 corresponds to the Kokubo’s
corrected SBF [1]; c-SBF3 is c-SBF2 equilibrated at 37 C with
p(CO2)¼ 0.05 atm; SBF-JL1 is c-SBF3 fromwhich K, Mg and sulphate
ions have been removed.
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The simplest SBF solution that can be thought of should be in
equilibrium with dicalcium phosphate dihydrate (DCPD; CaH-
PO4$2H2O) just like blood serum [33]. It should have a pH value close
to 7.4, an initial Ca concentration around2.5 mMand an ionic strength
around 140 mM [34]. Furthermore, it should be in equilibrium with
the physiological temperature and partial CO2 pressure (T¼ 37 C,
p(CO2)¼ 0.05 atm). Solution SBF-JL2matches these criteria.
Table III summarizes the thermochemical status of the solutions
before the occurrence of any precipitation, and after equilibration
with respect to HA. The expression ‘‘closed system evolution’’
means that no material exchange occurs between solution and
environment; speciﬁcally, the carbonate content of the system
remains constant. Otherwise, the carbonate content is in equilib-
rium with p(CO2)¼ 0.05 atm throughout the process.
Table III shows that all SBFs are initially oversaturated with
respect to calcite and to all the selected Ca phosphates except
DCPD. In contrast with the other solutions, c-SBF2 is initially in
equilibrium with p(CO2)¼ 0.006 atm. The fact that all the selected
SBFs are able to precipitate calcite and Ca phosphates other than HA
is interesting, in that it opens the possibility to test the selectivity
for a given material or surface treatment to nucleate selectively
different precipitates, or to test the promoting effect for HA
precipitation of soluble additives such as proteins or oligopeptides.
After equilibration with HA, c-SBF2 and SBF-JL2 become under-
saturated with respect to calcite, in contrast with solutions c-SBF3
and SBF-JL1. Notice that solution SBF-JL2, although its initial HA
saturation is close to the other solutions, is able to precipitate 36%
more HA.
Another interesting point is the pH evolution upon HA equili-
bration: the pH remains very close to 7.4, except for c-SBF2: in this
case, a pH drop down to 6.25 occurs, whereas p(CO2) increases up to
0.058. This point stresses the importance of conducting bioactivity
tests under constant p(CO2); this experimental constraint should
not be such of a problem, as incubators used for cell culture are
commonly equipped with a p(CO2) control and monitoring system.
Appendix II. Preparation procedure for SBF solutions
This appendix presents the recipes for preparing selected SBF
solutions. The reagents proposed have the same purity as those
presented in Table A2 in reference [1]. Besides the solid reagents,
a titrated 1.0 M HCl solution would be used. The amounts of
reagents are presented in Table IV: the main difference between
c-SBF2 and the Kokubo’s recipe is that TRIS is not used in the
preparation.
As successive mixing of solid reagents under stirring at 37 C
involves the risk of premature precipitation of HA or other potential
precipitates, an alternative way for SBF solutions preparation is
suggested. It consists in preparing separately in advance two stock
solutions, as shown in Table V: Solution Awould incorporate all the
solid reagents except CaCl2, plus half the prescribed HCl solution;
Solution B would incorporate CaCl2 and the other half of the
prescribed HCl. Solutions A and B are supposed to be mixed in a 1:1
volume ratio just at the beginning or the bioactivity test. These
solutions can be prepared at room temperature in a volumetric
ﬂask (1 L). The order of reagents incorporation would not be crit-
ical; however, it seems preferable to dilute ﬁrst the prescribed
volume of HCl solution in about 80% of the ﬁnal volume of distilled
water, and then to add the solid reagents (ending with NaHCO3 for
Table I
Speciﬁc features of selected simulated body ﬂuids.
Solution Speciﬁc features
c-SBF2 Original Kokubo’s c-SBF; ﬁxed carbonate concentration
(closed system evolution)
c-SBF3 Original Kokubo’s c-SBF; equilibrated with p(CO2)¼ 0.05 atm
SBF-JL1 c-SBF3 made free of K, Mg and sulphate; equilibrated with
p(CO2)¼ 0.05 atm
SBF-JL2 Solution saturated with DCPD, Ca/P¼ 1.67; equilibrated with
p(CO2)¼ 0.05 atm
Notice Initial pH adjusted at 7.40 with hydrochloric acid
Table II
Compositions of selected simulated body ﬂuids.
Ion Ion concentrations [mM]
c-SBF2 c-SBF3 SBF-JL1 SBF-JL2
Naþ 142.00 142.00 142.00 142.00
Kþ 5.00 5.00
Mg2þ 1.50 1.50
Ca2þ 2.50 2.50 2.50 2.31
HCO3
 4.20 35.23 34.90 34.88
HPO4
2 1.00 1.00 1.00 1.39
SO4
2 0.50 0.50
Cl 147.96 117.62 111.00 109.90
Table III
Thermochemical status of selected simulated body ﬂuids (T¼ 37 C).
Saturation levels of selected precipitates
c-SBF2 c-SBF3 SBF-JL1 SBF-JL2
Initial state
S(Calcite) 0.12 0.56 0.57 0.55
S(DCPD) 0.06 0.08 0.05 0.00
S(DCP) 0.16 0.16 0.17 0.23
S(OCP) 0.63 0.61 0.64 0.68
S(b-TCP) 0.75 0.73 0.75 0.79
S(HA) 1.42 1.40 1.42 1.45
pH 7.40 7.40 7.40 7.40
p(CO2) [atm] 0.59% 5.0% 5.0% 5.0%
After equilibration with HA
S(Calcite) 0.75 0.32 0.32 0.29
S(DCPD) 1.28 2.02 2.02 1.61
S(DCP) 1.06 1.79 1.80 1.39
S(OCP) 0.80 1.12 1.12 0.95
S(b-TCP) 0.77 0.92 0.92 0.84
S(HA) 0 0 0 0
pH 6.25 7.39 7.39 7.38
p(CO2) [atm] 5.8% 5.0% 5.0% 5.0%
DW(HA) [mg/L] 163.9 167.4 167.4 227.0
S(X) is the thermodynamic saturation level.
S(X)¼DGdiss(X)/RT ln 10, where DGdiss(X) is the free enthalpy of dissolution of
precipitate X, per mole of released primary solutes (e.g. HA, Ca5OH(PO4)3/
5Ca2þþOHþ 3PO43 releases 9 moles of primary solutes per mole of dissolving
HA).
S(X)> 0 indicates that compound X can precipitate; S(X)¼ 0 means that X is in
equilibrium with the solution.
DW(HA) [mg/L], amount of precipitable hydroxyapatite.
c-SBF2: closed system evolution (constant total carbonate content); all other solu-
tions are considered to be in equilibrium with p(CO2)¼ 0.05 atm.
Table IV
Preparation of selected simulated body ﬂuids.
Starting materials Weights of starting materials (g/L)
Formula MW [g/mol] Purity [–] c-SBF2 c-SBF3 SBF-JL1 SBF-JL2
NaCl 58.44 99.5% 8.035 6.213 6.173 6.129
NaHCO3 84.01 99.5% 0.355 2.974 2.947 2.945
KCl 74.55 99.5% 0.225 0.225
Na2HPO4$2H2O 177.99 99.0% 0.180 0.249
K2HPO4$3H2O 228.22 99.0% 0.231 0.231
MgCl2$6H2O 203.31 98.0% 0.311 0.311
CaCl2 110.99 95.0% 0.292 0.292 0.292 0.270
Na2SO4 142.04 99.0% 0.072 0.072
Volumes of HCl solution (mL/L)
HCl Aq. Sol. 1.00 M 0.160 0.850 0.900 0.934
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Solution A). The ﬁnal volume should be complemented with
distilled water after complete dissolution of the solid reagents.
Both solutions A and B are thermodynamically stable, provided
they are stored at room temperature in tight sterilizable bottles
(preferably in polypropylene). Special care should be taken to
prevent biological proliferation in Solution A (e.g. ultraﬁltration
before storage, storage in a dark place.); adding a minute quantity
of preservative (formaldehyde or sodium azide) might also help to
keep Solution A sterile.
The following procedure is suggested for the start of the
bioactivity test: (1) Equal volumes of solutions A and B are stored
separately in tightly closed plastic syringes, and conditioned at
37 C in the incubator used for the bioactivity test. (2) Prepare
a mixing device, consisting in two plastic inlet tubes ﬁxed to a Y
connector, the outlet of which is connected to a static mixer (e.g.
a plastic tubing of 5 mm inner diameter, ﬁlled wit a 10-stage Ken-
ics-type ‘‘butterﬂy’’ mixer). (3) Prepare a vessel dedicated to the
bioactivity test (e.g. a standard cell culture ﬂask, preferably new
and sterile), containing a specimen of the material to be tested. (4)
At the start of the bioactivity test, unplug the two syringes, and
connect them to the mixing device through an on-line ﬁlter (e.g.
0.25 micron). (5) Eject simultaneously at constant rate the contents
of the two syringes through the mixing device into the test vessel,
and place it in the incubator. (6) The proposed protocol allows the
successive preparation of several test vessels with the same batches
of solutions A and B. Thus, the reproducibility of the test should be
improved signiﬁcantly.
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Table V
Dual-solution preparation of selected simulated body ﬂuids (amounts for 2 L ﬁnal
mixture).
Starting materials Weights of starting materials (g/L)
c-SBF3 SBF-JL2
Formula MW [g/mol] Purity [–] Sol. A Sol. B Sol. A Sol. B
NaCl 58.44 99.5% 6.213 6.213 6.129 6.129
NaHCO3 84.01 99.5% 5.948 5.890
KCl 74.55 99.5% 0.450
Na2HPO4$2H2O 177.99 99.0% 0.498
K2HPO4$3H2O 228.22 99.0% 0.462
MgCl2$6H2O 203.31 98.0% 0.622
CaCl2 110.99 95.0% 0.584 0.540
Na2SO4 142.04 99.0% 0.144
Volumes of HCl solution (mL/L)
HCl 1.00 M Aq. Sol. [mL/L] 0.850 0.850 0.934 0.934
M. Bohner, J. Lemaitre / Biomaterials 30 (2009) 2175–2179 2179
